Table 2 Correlation between TDO2 expression and various molecules including cancer stem cell markers in renal cell carcinoma
From: Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
| Â | TDO2 expression, n (%) | Â | |
|---|---|---|---|
| Â | High | Low | p valuea |
ALDH1 | |||
 Positive | 32 (57.14) | 24 (42.86) | 0.5775 |
 Negative | 19 (63.33) | 11 (36.67) |  |
CD44 | |||
 Positive | 18 (78.26) | 5 (21.74) | 0.0306 |
 Negative | 33 (52.38) | 30 (47.62) |  |
CD133 | |||
 Positive | 10 (71.43) | 4 (38.67) | 0.3127 |
 Negative | 41 (56.94) | 31 (43.06) |  |
EGFR | |||
 Positive | 10 (33.33) | 20 (67.67) | 0.3089 |
 Negative | 31 (55.36) | 25 (44.64) |  |
HER2 | |||
 Positive | 9 (50.00) | 9 (50.00) | 0.3663 |
 Negative | 42 (61.76) | 26 (38.24) |  |
p53 | |||
 Positive | 21 (67.74) | 10 (32.26) | 0.2317 |
 Negative | 30 (54.55) | 25 (45.45) |  |